NEW YORK, June 4, 2026, 11:02 EDT
• Eikon Therapeutics traded 5.1% higher at $9.91 late in the morning session on Nasdaq.
• The average 12-month analyst price target, based on FactSet, ticked lower to $24.80.
• Market focus remains on the latest ASCO cancer trial data, with investors still debating the risks around an early-stage biotech like Eikon, which has no products approved yet.
Eikon Therapeutics shares gained 5.1% to $9.91 late Thursday morning, moving ahead of a firm biotech sector as the market looked at new analyst targets and cancer trial news from the recent IPO. The stock traded in a range of $9.37 to $10.06 on light volume, according to market data.
Eikon is still seen by investors as a post-IPO clinical-stage bet, not an earnings play. Shares on Thursday were about 45% under the $18 IPO price from February, when Eikon raised $381.2 million, according to .
Gains in the sector gave a lift. The SPDR S&P Biotech ETF and the iShares Nasdaq Biotechnology ETF, each tracking groups of biotech stocks, traded higher in the morning. The funds were up roughly 3.0% and 2.6%.
TradingView posted a FactSet-derived update showing Eikon’s average 12-month price target dropped to $24.80, down from $25.20. Analyst forecasts were spread from $5 to $32. The same update put consensus at “Buy” from six analysts, with five rating it a buy and one a sell. TradingView
Eikon said in a June 1 regulatory filing that enrollment finished for its Phase 2 TeLuRide-005 trial testing EIK1001 in first-line stage 4 non-small cell lung cancer. The objective response rate, or the percentage of patients whose tumors shrank by a set amount, came in at 63.1%. Disease control rate, counting both tumor shrinkage and stable disease, was 90.8%.
Eikon chief medical officer Roy Baynes said the biotech’s lead program had “encouraging response rates and durability.” He added that EIK1003 showed “meaningful clinical activity” both alone and when used with paclitaxel. Businessinsider
EIK1001, a TLR 7/8 dual agonist meant to trigger immune sensors, is in trials with Merck’s Keytruda (pembrolizumab) and chemo for lung cancer. Eikon’s PARP1 inhibitor program also goes up against bigger names. AstraZeneca and Gilead are listed in Eikon’s 10-K as companies with selective PARP1 drugs in the clinic.
Eikon reported $596 million in cash, cash equivalents and marketable securities at the end of the first quarter, enough to fund operations into the second half of 2027. The company said it lost $83 million for the quarter, more than the $74.5 million loss a year ago. Research and development spending climbed 24% to $70 million.
The risks with Eikon are clear. The company has no approved drugs, no product sales and admits it might never be profitable. Eikon’s filings point out clinical trials may get delayed or fail, and it could need more cash. In biotech, a bad trial result can knock down a valuation fast.
Eikon’s main drug is in a class that “historically struggled with systemic toxicity issues,” Lukas Muehlbauer, a research associate at IPOX, told Reuters when Eikon started trading. The company says its biomarker-guided dosing could balance immune activation with tolerability. Investors will be watching for more data to see if that works. Reuters
The next big point for Eikon is another clinical readout. The company says it expects the first interim analysis from its Phase 2/3 melanoma trial of EIK1001 plus pembrolizumab in the second half of 2026. That update could be a bigger deal for the stock than the move seen on Thursday.
